Clinical trial
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell…
NCT00056173 · Aptose Biosciences Inc., Industry · Completed
Key facts
| NCT number | NCT00056173 |
|---|---|
| Title | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma |
| Official title | A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC) |
| Lead sponsor | Aptose Biosciences Inc., Industry |
| Collaborators | Wake Forest University University of Chicago |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | GTI-2040 |
| Enrollment | 43 |
| Start date | Mar 1, 2002 |
| Primary completion | Dec 1, 2004 |
| First posted | Mar 10, 2003 |
| Last update posted | Jan 7, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: